VYNE vs. NXTC, KZR, MNOV, HOOK, PRTK, GOSS, VERU, CRVS, CTMX, and ADAG
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include NextCure (NXTC), Kezar Life Sciences (KZR), MediciNova (MNOV), Hookipa Pharma (HOOK), Paratek Pharmaceuticals (PRTK), Gossamer Bio (GOSS), Veru (VERU), Corvus Pharmaceuticals (CRVS), CytomX Therapeutics (CTMX), and Adagene (ADAG). These companies are all part of the "medical" sector.
NextCure (NASDAQ:NXTC) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
NextCure currently has a consensus target price of $6.00, suggesting a potential upside of 347.73%. VYNE Therapeutics has a consensus target price of $5.75, suggesting a potential upside of 159.01%. Given VYNE Therapeutics' higher possible upside, equities analysts clearly believe NextCure is more favorable than VYNE Therapeutics.
NextCure has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
NextCure has a net margin of 0.00% compared to NextCure's net margin of -6,874.47%. VYNE Therapeutics' return on equity of -53.29% beat NextCure's return on equity.
VYNE Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
42.7% of NextCure shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 1.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
NextCure received 53 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 63.93% of users gave NextCure an outperform vote while only 59.52% of users gave VYNE Therapeutics an outperform vote.
In the previous week, VYNE Therapeutics had 2 more articles in the media than NextCure. MarketBeat recorded 2 mentions for VYNE Therapeutics and 0 mentions for NextCure. VYNE Therapeutics' average media sentiment score of 0.00 equaled NextCure'saverage media sentiment score.
Summary
NextCure beats VYNE Therapeutics on 9 of the 15 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
